sur Theranexus (EPA:ALTHX)
THX Pharma Strengthens Financial Position in 2025
THX Pharma, known for its innovative focus on rare neurological diseases, released its 2025 results and cash position for March 2026. The company reported a cash reserve of €22.3 million, bolstered by agreements with Biocodex and Exeltis. These partnerships, alongside a capital increase, provide financial stability for years.
The strategic alliance with Biocodex is a landmark in THX Pharma's growth, involving Batten-1's Phase 3 trial costs. The agreement's total value could reach €173 million, including milestone payments and royalties.
Despite operating income primarily from grants, the company reported losses. The result reflects cost reductions and strategic adjustments in 2025, including a focus on R&D with partners like Diverchim.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus